Changes in US stocks | US clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) fell more than 10% after entering the US stock market and opening

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that on Friday, Retention Pharmaceuticals (RTSN.US) entered the US stock market. As of press release, the stock had fallen more than 10% to $10.77. The IPO price is $12. Retention Pharmaceuticals is an American clinical-stage biopharmaceutical company focused on developing innovative drugs to treat high blood pressure and other cardiovascular diseases. RTN-001, the company's core drug under development, is a next-generation phosphodiesterase 5 (PDE5) inhibitor. It is mainly aimed at patients with uncontrolled and intractable hypertension. Phase IIb clinical trials are currently being carried out. The drug helps dilate blood vessels and lower blood pressure by enhancing nitric oxide signaling in blood vessels. Its exclusive global development license comes from French pharmaceutical giant Sanofi-Aventis (SNY.US).